文献速递神经核医学核素与放射性配体治疗肿瘤 PET/CT

诊疗一体化在3级神经内分泌肿瘤中的作用评估

Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms.
PubMed 文献 · J Nucl Med · 2019-03-08

本文综述生长抑素受体(SSTR)显像与肽受体放射性核素治疗(PRRT)在3级神经内分泌肿瘤(G3 NEN)中的作用,包括对高分化G3 NEN的讨论。部分研究提示G3 NEN的SSTR显像阳性率低于高分化NEN而18F-FDG PET阳性率更高,但数据有限。13项研究共151例可评估影像学反应的患者中99例(66%)至少达疾病稳定或部分缓解,提示部分G3 NEN可对PRRT有反应。

要点

  • G3 NEN的Ki-67>20%、总生存<1年,与G1/G2的Ki-67<20%、总生存>10年不同。
  • SSTR显像阳性有助于筛选适合PRRT的患者,SSTR与18F-FDG显像不一致可能提示肿瘤生物学与预后线索。
  • 建议G3 NEN患者同时接受18F-FDG PET与SSTR显像以辅助诊断和治疗选择。

核心结论

  • 部分G3 NEN可对PRRT有反应,但证据有限,尚需前瞻性研究明确PRRT在G3 NEN中的作用。

研究设计与样本

  • 本文为综述,汇总SSTR显像与PRRT在G3 NEN中的研究,并讨论高分化G3 NEN这一最新组织学分类。

主要发现

  • 仅13项研究提及PRRT用于G3 NEN,这些研究中可测量影像学反应的患者共151例。
  • 151例中99例(66%)至少达疾病稳定或部分缓解。
  • 部分研究提示G3 NEN的SSTR显像阳性可能性低于高分化NEN,而18F-FDG PET阳性可能性更高,但数据有限。

关键数值与推荐

  • 高分化G1和G2 NEN的Ki-67<20%、总生存>10年;G3 NEN的Ki-67>20%、总生存<1年。
  • 177Lu-DOTATATE于2018年获美国FDA批准用于胃肠胰NEN,依据是III期临床试验中高分化中肠NEN较 high-dose octreotide long-acting release 延长无进展生存。

临床怎么用

  • G3 NEN患者应同时接受18F-FDG PET与SSTR显像,以辅助诊断和治疗选择。
  • SSTR显像阳性有助于识别适合PRRT的患者,显像不一致可能提示肿瘤生物学与预后线索。

局限性

  • 关于G3 NEN的SSTR显像阳性率低于高分化NEN的数据有限。
  • 提及PRRT用于G3 NEN的研究仅13项、可测量影像学反应的患者仅151例。
  • 需要前瞻性研究以充分理解PRRT在G3 NEN中的作用,尤其是高分化与低分化G3病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnosis and subsequent therapy of neuroendocrine neoplasms (NENs) have long relied on somatostatin receptor (SSTR) expression. The field of theranostics now uses newer SSTR-based PET imaging with 68Ga-DOTATATE or 68Ga-DOTATOC as a prerequisite for the administration of peptide receptor radionuclide therapy (PRRT). In the United States, Food and Drug Administration approval of 177Lu-DOTATATE, a form of PRRT, in 2018 for use in gastroenteropancreatic NENs was obtained on the basis of prolonged progression-free survival versus high-dose octreotide long-acting release in a phase III clinical trial of well-differentiated midgut NENs. Well-differentiated grade 1 and grade 2 NENs have a low proliferation index (Ki-67 < 20%) and longer overall survival (>10 y), whereas higher-grade (grade 3 [G3]) NENs have a high Ki-67 (>20%) and shorter overall survival (<1 y). Here, we present a review on the role of SSTR-based imaging and PRRT in G3 NENs, including a discussion of well-differentiated G3 NENs, the newest histologic classification. Some studies suggest that G3 NENs are less likely to be positive on SSTR-based imaging (but more likely on 18F-FDG PET) than are well-differentiated NENs, but these data are limited. We found only 13 studies mentioning the use of PRRT in G3 NENs and a total of only 151 patients across these studies in whom radiologic response was measured. Of these 151 patients, 99 (66%) demonstrated at least stable disease or a partial response, indicating that some G3 NENs can be responsive to PRRT. We suggest that patients with G3 NENs should receive both 18F-FDG PET and SSTR-based imaging to aid in both diagnosis and treatment selection, as positivity on SSTR-based imaging helps with patient identification for PRRT and discordance may suggest important clues to tumor biology and prognosis. However, prospective studies are needed to fully understand the role of PRRT in G3 NENs, especially in well- versus poorly differentiated G3 disease.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Waseem N, Aparici CM, Kunz PL, et al. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. J Nucl Med. 2019. PMID: 30850504. doi:10.2967/jnumed.118.217851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。